Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hyperion Therapeutics Inc announces publication of phase two results of Glycerol Phenylbutyrate (GPB) for treatment of hepatic encephalopathy in hepatology


Tuesday, 25 Feb 2014 09:05am EST 

Hyperion Therapeutics Inc:Announces results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology.Says the study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.Says patients were randomized in a 1:1 ratio to receive 6 mL GPB or placebo, orally, twice daily for 16 weeks.Says the primary endpoint was the proportion of patients with HE events.Says among patients taking rifaximin at baseline, there was no difference in the proportion of patients with events or total events, although a non-significant trend was observed with respect to fewer hospitalizations in patients randomized to GPB.